Long term prognosis of chronic inflammatory demyelinating polyneuropathy: A five year follow up of 38 cases

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 77, Issue 1, 2006, Pages 66-70

  Kuwabara, Satoshi ^a   Misawa, S ^a   Mori, M ^a   Tamura, N ^a   Kubota, M ^a   Hattori, T ^a  

^a CHIBA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN; IMMUNOMODULATING AGENT;

ADULT; ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DEMYELINATION; ELECTROPHYSIOLOGY; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; MALE; NERVE CONDUCTION; NERVE ENDING; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REMISSION; SYMPTOM; TREATMENT OUTCOME;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; PLASMAPHERESIS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PROGNOSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 29644436754     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.065441     Document Type: Article

References (21)

1. Ad Hoc Subcommittee. American Academy of Neurology AIDS Task Force. Research criteria for chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617-18.
2. Dyck PJ, Lais AC, Ohta M, et al. Chronic inflammatory demyelinating polyradiculoneuropathy. Mayo Clin Proc 1975;50:621-37.
3. McCombe PA, Pollard JD, Mcleod JG. Chronic inflammatory demyelinating polyradiculoneuropathy. Brain 1987;110:1617-30.
4. Barohn RJ, Kissel JT, Warmolts JR, et al. Chronic inflammatory demyelinating polyradiculoneuropathy. Clinical characteristics, course, and recommendations for diagnostic criteria. Arch Neurol 1989;46:878-4.
5. Simmons Z, Albers JW, Bromberg MB, et al. Presentation and initial clinical course in patients with chronic inflammatory demyelinating polyradiculoneuropathy: comparison of patients without and with monoclonal gammopathy. Neurology 1993;43:2202-9.
6. Sghirlanzoni A, Solari A, Ciano C, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: long-term course and treatment of 60 patients. Neurol Sci 2000;21:31-7.
7. Mygland A, Monstad P, Vedeler C. Onset and course of chronic inflammatory demyelinating polyneuropathy. Muscle Nerve 2005;31:589-93.
8. Bouchard C, Lacroix C, Plante V, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999;52:498-503.
9. Kuwabara S, Ogawara K, Misawa S, et al. Distribution patterns of demyelination correlate with clinical profiles in chronic inflammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 2002;72:37-42.
10. Pestronk A, Cornblath DR, Ilyas AA, et al. A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside. Ann Neurol 1988;24:73-8.
11. Chaudhry V, Corse AM, Cornblath DR, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol 1993;33:237-42.
12. Saperstein DS, Amato AA, Wolfe GI, et al. Multifocal acquired demyelinative sensory and motor neuropathy: the Lewis-Sumner syndrome. Muscle Nerve 1999;22:560-6.
13. Simmons Z, Albers JW, Bromberg MB, et al. Long-term follow-up of patients with chronic inflammatory demyelinating polyradiculoneuropathy, without and with monoclonal gammopathy. Brain 1995;118:359-68.
14. Shahani BT, Young RR, Potts F, et al. Terminal latency index (TLI) and late response studies in motor neuron disease (MND), peripheral neuropathies and entrapment syndromes [abstract]. Acta Neurol Scand 1979;73(suppl):118.
15. Bromberg MB, Albers JW. Patterns of sensory nerve conduction abnormalities in demyelinating and axonal peripheral nerve disorders. Muscle Nerve 1993;16:262-6.
16. Olsson Y. Topographical differences in the vascular permeability of the peripheral nervous system. Acta Neuropathol 1968;10:26-33.
17. Brown WF, Snow R. Patterns and severity of conduction abnormalities in Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1994;54:768-74.
18. Kuwabara S, Mori M, Ogawara K, et al. Axonal involvement at the common entrapment sites in Guillain-Barre syndrome with IgG anti-GM1 antibody. Muscle Nerve 1999;22:840-5.
19. Dyck PJ, Litchy WJ, Kratz KM, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994;36:838-45.
20. Hall SM, Redford EJ, Smith KJ. Tumor necrosis factor-α has few morphological effects within the dorsal columns of the spinal cord, in contrast to its effects in the peripheral nervous system. J Neuroimmunol 2000;106:130-6.
21. Misawa S, Kuwabara S, Mori M, et al. Serum levels of tumor necrosis factor-α in chronic inflammatory demyelinating polyneuropathy. Neurology 2001;56:666-9.